18 July 2024 in Journal of Pre-Clinical and Clinical Research
Introduction: According to 2023 statistics in the United States, penetrating eye injuries are not infrequent. Mishandling a penetrating eye injury can lead to irreversible blindness of the the patient. Therefore, proper response from doctors and prompt surgical intervention with a well-planned...
30 June 2023 in OphthaTherapy. Therapies in Ophthalmology
Dry eye syndrome is a group of medical conditions that can be caused by many factors, as a result of which there is an abnormality in moisturizing of the eye surface by a tear film. One of the causes of this disorder is Sjögren’s syndrome, which is an autoimmune disease in which the body produces antibodies against its own proteins. The glands of external secretion, mainly lacrimal and salivary glands are damaged as a result of inflammation. Associated with this side effects, affect negatively and reduce the quality of life, which is why in the following article we present the available therapeutic options for patients suffering from ophthalmological manifestations of Sjögren’s syndrome.
27 December 2023 in OphthaTherapy. Therapies in Ophthalmology
Keratitis and subsequent damage to the cornea resulting from infectious causes is one of the most serious problems facing ophthalmology today. One of the most common etiologies is fungal infection. Symptoms range from pain and visual deterioration, Wessely ring, inflammatory reaction in the anterior chamber or ropost. Diagnosis in addition to the classic medical and ophthalmologic examination consists of microscopic examination of scrapings, Gram examination combined with culture gives a 90% chance of detecting a fungal etiology. Good results are also observed with PCR testing, which helps speed up diagnosis. Treatment is time-consuming and has a high risk of complications. Two techniques are used to treat fungal infections of the cornea, surgical and pharmacological, such as the antifungal polyene antibiotics nystatin, natamycin, amphotericin B or thiazole derivatives like fluconazole and voriconazole. For filamentous fungi, natamycin 5% or voriconazole 1% are used at various intervals. Natamycin, despite the much poorer availability of the drug in countries such as Africa, has much better clinical results along with a lower risk of complications, as confirmed by the MUTT. A big problem also is subsequent bacterial superinfection, leading to the need for topical antibiotics. Surgical treatment is used in case of failure of pharmacotherapy, up to 4 weeks after the diagnosis of the disease, but it carries a high risk of complications. In the early stages of the disease, a new cross-linking technique can be considered, which is described as an alternative to direct antifungal or antibacterial treatment.
30 September 2024 in OphthaTherapy. Therapies in Ophthalmology
Therapeutic options in inflammatory glaucoma, both pharmacological and surgical methods, have been presented in this paper. Main goals of pharmacotherapy are: controlling inflammation and reducing intraocular pressure. Anti-inflammatory drugs primarily include topical glucocorticosteroids but also nonsteroidal anti-inflammatorydrugs and immunomodulatory therapy. Elevated intraocular pressure is treated with β-blockers, carbonic anhydrase inhibirozpotors, prostaglandin analogues and α2-adrenergic receptor agonists. If pharmacological treatment does not produce the desired results, surgical treatment must be considered. Due to the risk of reactivation of inflammation, it is recommended that it be performed 3 months after the inflammation has healed. Currently, trabeculectomy remains the gold standard. Among the invasive treatment techniques, we discuss trabeculectomy with the use of mitomycin C, micro-hook trabeculectomy, laser therapy, glaucoma drainage implants, deep sclerectomy and viscocanalostomy.
31 March 2023 in OphthaTherapy. Therapies in Ophthalmology
Submacular hemorrhage treatment is still an important issue in ophthalmology. At present we lack algorithms of treatment that could be used in clinical practice. Efficacy of every treatment method seems to differ by individual factors simultaneously existing in each patient. Therefore, anti-VEGF agents remain crucial in treating patients with coexisting vasculopathy, while in posttraumatic hemorrhage we should lean towards other approaches, like pneumatic displacement. Operative methods, despite being more invasive and burdened with higher potential risk, are indispensable in large hemorrhages, significantly speeding up clot removal. The primary aim of this work is to collect recent data regarding this issue and to determine usefulness of treatment methods in specific cases, regarding factors such as hemorrhage pathophysiology. The following article pertains to currently used treatment methods, such as: pneumatic displacement, anti-VEGF therapy, rtPA and operative methods.
28 November 2024 in OphthaTherapy. Therapies in Ophthalmology
This paper discusses scleritis in the course of systemic autoimmune diseases such as rheumatoid arthritis, nodular arteritis and granulomatosis with vasculitis. In addition, treatment suggestions based on the available literature are presented. Patients with scleritis resulting from an underlying disease should be twardiagnosed as soon as possible and given appropriate and effective treatment. Untreated or poorly treated scleritis or underlying disease can lead to severe damage to ocular tissues, loss of vision and eventually even blindness. A meticulous medical history, detailed ophthalmic examination and a series of targeted investigations as part of a multidisciplinary approach to detect any systemic disease are important in the management of scleritis. Rheumatoid arthritis remains the most common systemic rheumatic disease and the most common systemic condition associated with scleritis.